Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT05540262
Recruiting Not applicable

Edaravone in the Treatment of Optic Neuritis

NCT05540262 · tracked via the Priya Life Science China tracker
Sponsor
First Affiliated Hospital of Guangxi Medical University
Phase
Not applicable
Started
2022-01-15
Last updated
2025-02-27

Condition(s) studied

Optic Neuritis

Investigational drug(s) / intervention(s)

Edaravone →

Edaravone: Edaravone injection 30mg three times a day

Study summary

Edaravone has demonstrated a beneficial effect in promoting remyelination and protecting axons in animals with NMOSD. The researchers posit that edaravone may enhance visual outcomes in patients with aquaporin-4 antibody-positive optic neuritis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: 1. Chinese patients aged ≥18 with anti-aquaporin-4 antibody-positive optic neuritis 2. Patients with a first episode of optic neuritis in either eye 3. First symptoms of optic neuritis ≤30 days prior to the first administration of edaravone Exclusion Criteria: 1. Myopia over 6 diopters 2. Refractive media opacity affecting assessment of retinal layers and/or visual acuity

Primary outcome measure(s)

  • Best-corrected visual acuity — 18 months
    Best-corrected visual acuity will be measured by "Illiterate E"chart.

Trial sites (1)

FacilityCityRegionStatus
Yi Du Nanning China Recruiting

More First Affiliated Hospital of Guangxi Medical University trials in China

CascadeDiagnose Prostate MRI Starting soon
Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma Starting soon
An International Multicenter Clinical Study on Application of UroMed AI Doctor Based on Large Language Models Starting soon
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer Active, not recruiting
Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging Recruiting

Other trials for the same condition

Prospective Evaluation of the 2022 Optic Neuritis Criteria When Optic Neuritis Is Suspected Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05540262 on ClinicalTrials.gov ↗ ← All trials in China